Abstract
This review provides an overview of the role of long-term treatment of severe asthma with oral corticosteroids (OCS) and its associated side-effects in adults. It is based on a systematic literature search conducted in MEDLINE, Embase and the Cochrane Library to identify relevant studies. After a short overview of severe asthma and its treatment we present studies showing a dose–response relationship in asthmatic patients treated with OCS and then consider by organ systems the undesired effects demonstrated in clinical and epidemiological studies in patients with OCS-dependent asthma. It was found that the risk of developing various OCS-related complications, including infections, diabetes and osteoporosis as well as psychiatric disorders, was higher for patients with long-term exposure to OCS compared with control groups. In addition, studies showed a significant increase in healthcare resource utilisation due to OCS treatment. Therefore, it is incumbent on every clinician to carefully weigh the potential benefit of preventing loss of asthma control against this risk before opting to prescribe long-term OCS therapy. Effective corticosteroid-sparing strategies must be used and should aim at short-term use with the lowest effective dose and start tapering as soon as possible until OCS therapy is terminated.
Abstract
Although oral corticosteroids are effective, due to side-effects corticosteroid-sparing strategies must be used and one should aim at short-term use with the lowest effective dose and start tapering as soon as possible until OCS therapy is terminated http://ow.ly/F8wU30ltEXc
Footnotes
This article has supplementary material available from erj.ersjournals.com
Conflict of interest: T. Volmer reports grants from Teva Pharmaceutical Industries Ltd, during the conduct of the study; and personal fees for consultancy from Teva Pharmaceutical Industries Ltd, outside the submitted work.
Conflict of interest: T. Effenberger reports grants from Teva Pharmaceutical Industries Ltd, during the conduct of the study; and personal fees for consultancy from Teva Pharmaceutical Industries Ltd, outside the submitted work.
Conflict of interest: C. Trautner reports grants from Teva Pharmaceutical Industries Ltd, during the conduct of the study; and personal fees for consultancy from Teva Pharmaceutical Industries Ltd, outside the submitted work.
Conflict of interest: R. Buhl reports grants from Teva Pharmaceutical Industries Ltd, during the conduct of the study; and personal fees for consultancy from Teva Pharmaceutical Industries Ltd, outside the submitted work.
Support statement: This research was partly funded through a restricted grant from Teva. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received April 13, 2018.
- Accepted August 13, 2018.
- Copyright ©ERS 2018
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org